Scholarlink

Background <p>Current treatment modalities can only reap a limited efficacy in reversing myocardial damage and promoting functional recovery in patients with myocardial infarction. Therefore, there is an urgent need to explore new therapeutic approaches to enhance cardiac repair.</p> Methods <p>MSCs were pretreated with empagliflozin to obtain EMPA-EVs, with non-pretreated MSC-EVs serving as controls. In vitro experiments were conducted to evaluate the effects of the two types of EVs on macrophage phenotypic transformation, cardiomyocyte apoptosis, and vascular endothelial cell lumen formation. In vivo experiments, a rat model of myocardial infarction was constructed, and EMPA-EVs, non-pretreated MSC-EVs, or phosphate-buffered saline were administered via myocardial injection. Post-treatment assessments included left ventricular ejection fraction, myocardial infarction area, and levels of pro-inflammatory cytokines in myocardial tissue. In addition, AGGF1 was depleted in EMPA-EVs to observe their anti-apoptotic, anti-inflammatory, and pro-angiogenic effects.</p> Results <p>Compared with non-pretreated MSC-EVs, EMPA-EVs increased the proportion of macrophages transforming into anti-inflammatory phenotypes, decreased the rate of apoptotic cardiomyocytes, and promoted the formation of vascular endothelial cell lumen. Animal experiments showed that the left ventricular ejection fraction of rats in the EMPA-EVs group was higher than that in the control group, the myocardial infarction area was reduced, and the level of pro-inflammatory factors in myocardial tissue decreased. Moreover, AGGF1 expression was significantly upregulated in EMPA-EVs, and the anti-apoptotic, anti-inflammatory, and pro-angiogenic effects of EMPA-EVs were inhibited upon <i>AGGF1</i> knockdown.</p> Conclusion <p>EMPA-EVs can promote cardiac repair in myocardial infarction, and this therapeutic effect involves the upregulation of AGGF1 and may promise a cell-free therapeutic strategy.</p> Graphical Abstract <p><b>MSC-EVs pretreated with empagliflozin exerted myocardial protective functions after myocardial infarction at least partially by activating the AGGF1/AKT signaling pathway to synergistically inhibit myocardial cell apoptosis, regulate the transformation of macrophages to pro-repair phenotypes, and promote angiogenesis</b></p> <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Empagliflozin-pretreated mesenchymal stem cell-derived extracellular vesicles facilitate cardiac repair via AGGF1

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月29日

查看全文
  • Qianwen Chen,
  • Qingqing Gu,
  • Jun Wei,
  • Li Deng,
  • Ye Deng,
  • Jingyi Wang,
  • Jianya Huang,
  • Tingting Sun,
  • Lu Pan,
  • Wenjun Mao,
  • Qingjie Wang,
  • Ruxing Wang,
  • Ling Sun

摘要

Background

Current treatment modalities can only reap a limited efficacy in reversing myocardial damage and promoting functional recovery in patients with myocardial infarction. Therefore, there is an urgent need to explore new therapeutic approaches to enhance cardiac repair.

Methods

MSCs were pretreated with empagliflozin to obtain EMPA-EVs, with non-pretreated MSC-EVs serving as controls. In vitro experiments were conducted to evaluate the effects of the two types of EVs on macrophage phenotypic transformation, cardiomyocyte apoptosis, and vascular endothelial cell lumen formation. In vivo experiments, a rat model of myocardial infarction was constructed, and EMPA-EVs, non-pretreated MSC-EVs, or phosphate-buffered saline were administered via myocardial injection. Post-treatment assessments included left ventricular ejection fraction, myocardial infarction area, and levels of pro-inflammatory cytokines in myocardial tissue. In addition, AGGF1 was depleted in EMPA-EVs to observe their anti-apoptotic, anti-inflammatory, and pro-angiogenic effects.

Results

Compared with non-pretreated MSC-EVs, EMPA-EVs increased the proportion of macrophages transforming into anti-inflammatory phenotypes, decreased the rate of apoptotic cardiomyocytes, and promoted the formation of vascular endothelial cell lumen. Animal experiments showed that the left ventricular ejection fraction of rats in the EMPA-EVs group was higher than that in the control group, the myocardial infarction area was reduced, and the level of pro-inflammatory factors in myocardial tissue decreased. Moreover, AGGF1 expression was significantly upregulated in EMPA-EVs, and the anti-apoptotic, anti-inflammatory, and pro-angiogenic effects of EMPA-EVs were inhibited upon AGGF1 knockdown.

Conclusion

EMPA-EVs can promote cardiac repair in myocardial infarction, and this therapeutic effect involves the upregulation of AGGF1 and may promise a cell-free therapeutic strategy.

Graphical Abstract

MSC-EVs pretreated with empagliflozin exerted myocardial protective functions after myocardial infarction at least partially by activating the AGGF1/AKT signaling pathway to synergistically inhibit myocardial cell apoptosis, regulate the transformation of macrophages to pro-repair phenotypes, and promote angiogenesis